Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELOS: Efficacy and Safety of PT009 in Moderate to Very Severe COPD
NCT02766608Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- May 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of budesonide + formoterol in chronic obstructive pulmonary disease (COPD), sponsored by Pearl Therapeutics. Started May 2016; status: completed.
02
Drugs
budesonide + formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02766608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766608.